Adverum Biotechnologies, INC Form 4 insider transactions
Director Reed Tuckson of Adverum Biotechnologies was granted stock options exercisable at $7.32, vesting on June 17, 2025, or the 2025 annual meeting, as reported in a Form 4 filing.
Director Scott M. Whitcup acquired 10,520 stock options in Adverum Biotechnologies on June 17, 2024, according to a Form 4 filing.
Director James Paul Scopa acquired 10,520 stock options in Adverum Biotechnologies, Inc. on June 17, 2024, according to a Form 4 filing with the SEC.
Patrick Machado, a director at Adverum Biotechnologies, acquired stock options on June 17, 2024, according to a Form 4 filing with the SEC.
Szilard Kiss, a director of Adverum Biotechnologies, acquired 21,040 stock options on June 17, 2024, as reported in a Form 4 filing with the SEC.
Form 4: Adverum Biotechnologies Executive Acquires 85,000 Stock Options Following Performance Milestone
Setareh Seyedkazemi, Chief Development Officer of Adverum Biotechnologies, acquired 85,000 stock options after a performance condition related to the LUNA trial was met.
Peter Soparkar, Chief Operating Officer of Adverum Biotechnologies, acquired 130,000 shares through the vesting of performance stock options.
Adverum Biotechnologies CEO Laurent Fischer acquired 315,000 shares of common stock through the vesting of performance-based stock options.